Gene:
CCND1
cyclin D1

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs9344 *1365+4648C>T, 12038G>A, 14768705G>A, 69462910G>A, 723G>A, CCND1 (A870G), CCND1:870G>A, Pro241=, rs603965
G > A
Intronic
Pro241Pro
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  B-cell CLL/lymphoma 1; BCL1; D11S287E; G1/S-specific cyclin D1; PRAD1; parathyroid adenomatosis 1
Alternate Symbols:  U21B31
PharmGKB Accession Id: PA75

Details

Cytogenetic Location: chr11 : q13.3 - q13.3
GP mRNA Boundary: chr11 : 69455873 - 69469242
GP Gene Boundary: chr11 : 69445873 - 69472242
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. btg family proteins and cell cycle regulation - (BioCarta via Pathway Interaction Database)
  2. Canonical Wnt signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  3. cell cycle: g1/s check point - (BioCarta via Pathway Interaction Database)
  4. Coregulation of Androgen receptor activity - (Pathway Interaction Database NCI-Nature Curated)
  5. Cyclin D associated events in G1 - (Reactome via Pathway Interaction Database)
  6. cyclins and cell cycle regulation - (BioCarta via Pathway Interaction Database)
  7. E-cadherin signaling in the nascent adherens junction - (Pathway Interaction Database NCI-Nature Curated)
  8. FOXM1 transcription factor network - (Pathway Interaction Database NCI-Nature Curated)
  9. inactivation of gsk3 by akt causes accumulation of b-catenin in alveolar macrophages - (BioCarta via Pathway Interaction Database)
  10. influence of ras and rho proteins on g1 to s transition - (BioCarta via Pathway Interaction Database)
  11. Neurotrophic factor-mediated Trk receptor signaling - (Pathway Interaction Database NCI-Nature Curated)
  12. p53 signaling pathway - (BioCarta via Pathway Interaction Database)
  13. Presenilin action in Notch and Wnt signaling - (Pathway Interaction Database NCI-Nature Curated)
  14. Regulation of Telomerase - (Pathway Interaction Database NCI-Nature Curated)
  15. Signaling mediated by p38-gamma and p38-delta - (Pathway Interaction Database NCI-Nature Curated)
  16. Trk receptor signaling mediated by PI3K and PLC-gamma - (Pathway Interaction Database NCI-Nature Curated)
  17. Ubiquitin-dependent degradation of Cyclin D1 - (Reactome via Pathway Interaction Database)
  18. wnt signaling pathway - (BioCarta via Pathway Interaction Database)
No related genes are available

Curated Information ?

Curated Information ?

Publications related to CCND1: 25

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014. Lopez-Lopez Elixabet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expression profiling of breast cancer patients treated with tamoxifen: prognostic or predictive significance. Medical oncology (Northwood, London, England). 2014. Tabarestani Sanaz, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature genetics. 2013. Toy Weiyi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Emerging landscape of oncogenic signatures across human cancers. Nature genetics. 2013. Ciriello Giovanni, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy. The pharmacogenomics journal. 2013. Absenger G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients. European journal of clinical pharmacology. 2013. Jekic Biljana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012. Labonte M J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. The pharmacogenomics journal. 2011. Salazar J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC cancer. 2011. Dahan Laetitia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. The pharmacogenomics journal. 2010. Miller W R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. The pharmacogenomics journal. 2010. Ho-Pun-Cheung A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression. PloS one. 2010. Nencioni Alessio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008. Ben Sahra I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood. 2008. Dulucq St├ęphanie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glucocorticoid receptor gene polymorphisms in premenopausal women with major depression. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et m├ętabolisme. 2008. Krishnamurthy P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008. Graziano Francesco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. The Journal of biological chemistry. 2008. Liu Zhengyu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of EGFR and VEGF inhibition. Drug discovery today. 2007. Pander Jan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. Journal of molecular signaling. 2008. Zhuang Yongxian, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica. 2006. Costea Irina, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenetics and genomics. 2006. Zhang Wu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. American journal of hematology. 2006. Zhang Guang-Sen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005. Patel Manish I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to S phase. The Journal of biological chemistry. 2005. Qin Ling, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenetics. 2003. Costea Irina, et al. PubMed

LinkOuts

Entrez Gene:
595
OMIM:
114500
151400
168461
193300
254500
UCSC Genome Browser:
NM_053056
RefSeq RNA:
NM_053056
RefSeq Protein:
NP_444284
RefSeq DNA:
AC_000054
AC_000143
NC_000011
NG_007375
NT_167190
NW_001838027
NW_925106
UniProtKB:
CCND1_HUMAN (P24385)
Q6FI00_HUMAN (Q6FI00)
Ensembl:
ENSG00000110092
GenAtlas:
CCND1
GeneCard:
CCND1
MutDB:
CCND1
ALFRED:
LO000284O
HuGE:
CCND1
Comparative Toxicogenomics Database:
595
ModBase:
P24385
HumanCyc Gene:
HS03287
HGNC:
1582

Common Searches